Wall Street analyst estimates for Edesa Biotech, Inc. (EDSA): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Edesa Biotech, Inc. is a biopharmaceutical firm focused on discovering, developing, and commercializing clinical-stage treatments for inflammatory and immune system disorders where current medical options are inadequate.
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-12-11 | $-0.58 | ||
| 2026-08-13 | $-0.60 | $-0.43 | -37.9% |
| 2026-05-14 | $-0.49 | $-0.24 | -104.2% |
| 2026-02-13 | $-0.28 | $-0.28 | +0.0% |
| 2025-12-12 | $-0.32 | $-0.27 | -18.5% |
| 2025-08-08 | $-0.25 | $-0.26 | +3.8% |
| 2025-05-14 | $-0.30 | $-0.30 | +0.0% |
| 2025-02-14 | $-0.48 | $-0.31 | -54.8% |
Valuation Ratios
| Price / Book | 3.96 |
| EV / EBITDA | -2.46 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.3M | $228287 | $211849 | $410870 | $328801 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | $1.1M | $534453 | $445320 | $101286 | $17601 | $118788 | 0 | 0 | 0 | $119273 |
| Gross Profit | $143861 | -$306166 | -$233471 | $309584 | $311200 | -$118788 | 0 | 0 | 0 | -$119273 |
| Research & Development | $1.7M | $2.0M | $2.1M | $1.1M | $3.3M | $17.9M | $13.3M | $4.8M | $2.9M | $3.7M |
| Selling, General & Admin | $3.3M | $2.9M | $2.8M | $2.0M | $3.4M | $5.7M | $5.0M | $4.4M | $4.1M | $4.2M |
| Operating Expenses | $5.1M | $4.9M | $4.8M | $3.1M | $6.7M | $23.7M | $18.4M | $9.2M | $7.0M | $7.8M |
| Operating Income | -$4.9M | -$5.2M | -$5.1M | -$2.8M | -$6.4M | -$23.7M | -$18.4M | -$9.2M | -$7.0M | -$7.9M |
| EBITDA | -$4.9M | -$4.9M | -$4.8M | -$2.8M | -$6.3M | -$13.2M | -$17.5M | -$8.5M | -$6.1M | -$7.1M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Pre-tax Income | -$5.0M | -$5.0M | -$5.0M | -$2.8M | -$6.4M | -$13.3M | -$17.5M | -$8.4M | -$6.2M | -$7.2M |
| Income Tax | $7200 | $800 | $800 | -$55404 | $800 | $800 | $800 | $800 | $800 | $800 |
| Net Income | -$5.0M | -$5.0M | -$5.0M | -$2.7M | -$6.4M | -$13.3M | -$17.5M | -$8.4M | -$6.2M | -$7.2M |
| EPS | $-23.92 | $-36.78 | $-3.32 | $-4.79 | $-5.18 | $-7.73 | $-8.37 | $-2.93 | $-1.93 | $-1.27 |
| EPS (Diluted) | $-23.92 | $-36.78 | $-3.32 | $-4.79 | $-5.18 | $-7.73 | $-8.37 | $-2.93 | $-1.93 | $-1.27 |
| Shares Outstanding (Diluted) | $210150 | $23810 | $462843 | $655318 | $1.2M | $1.7M | $2.1M | $2.9M | $3.2M | $5.7M |
Price
| Price | $3.87 |
| Market Cap | $37M |
| Exchange | NASDAQ |
| Country | CA |
Related companies: BRTX · COCP · DWTX · ERNA · EVGN · IMNN · IMRN
Explore sector: Healthcare · Biotechnology
More sections of EDSA: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks